Diana Buist, PhD, MPH, is an epidemiologist and health services researcher with extensive experience conducting comparative effectiveness research. Her work focuses on reducing harms and increasing benefits for patients in the area of cancer screening and outcomes spanning across patient, provider, and system factors.
Dr. Buist has an extensive record of practical research that has led to many efforts to improve care, including the development and refinement of national breast cancer screening guidelines and their implementation within Kaiser Permanente Washington. She has been conducting research within Kaiser Permanente Washington for more than 20 years and is a strong believer in patient-centered care and the important role patients play in improving the value and quality of health care. Dr. Buist is involved in several studies aimed at providing high-value health care that provides patients and their providers with information on the expected benefits and harms of cancer screening and treatment strategies.
Dr. Buist also has a long history collaborating with external researchers, including helping lead two large national research consortia focused on improving cancer screening and outcomes: the National Cancer Institute’s Breast Cancer Surveillance Consortium and the Cancer Research Network of the Health Care Systems Research Network. Her extensive experience working with diverse data from these consortia in longitudinal studies and randomized trials in clinical systems puts Dr. Buist in a unique position to examine screening, care, and outcomes in health systems across the country.
As Kaiser Permanente Washington Health Research Institute (KPWHRI) Director of Research and Strategic Partnerships, Dr. Buist works with other Kaiser Permanente regions, our local academic partners, and other external collaborators to build enduring strategic partnerships to enhance KPWHRI’s mission, align with KPWHRI faculty research priorities, and capitalize on our unique strengths in ways that are consistent with our mission.
Dr. Buist contributes to a variety of other projects at KPWHRI, including:
Dr. Buist is also an affiliate professor in the Departments of Epidemiology and Health Services at the University of Washington School of Public Health and an affiliate member at Fred Hutchinson Cancer Research Center. She enjoys sharing her expertise by mentoring junior faculty and PhD and MPH candidates and teaching courses.
Cancer screening and prevention; outreach and primary care prevention; comparative effectiveness; cost transparency; surveillance; secondary prevention; breast cancer treatment; breast cancer screening; outcomes following cancer diagnosis; cancer survivorship; provider variability in care
Cancer prevention and control; quality of care; preventive care; high-value care; consumer engagement in preventive medicine; systematic reviews
Cancer prevention and control
Barlow WE, Taplin SH, Yoshida CK, Buist DS, Seger D, Brown M. A cost comparison of mastectomy versus breast-conserving therapy for early-stage breast cancer. J Natl Cancer Inst. 2001;93(6):447-55. PubMed
Phelan EA, Buist DS, Anderson LA, Newton KM, Delaney KM, LaCroix AZ. Understanding attitudes of older women toward hormone replacement therapy. Prev Med. 2001;32(1):49-56. PubMed
Buist DS, LaCroix AZ, Black DM, Harris F, Blank J, Ensrud K, Edgerton D, Rubin S, Fox KM. Inclusion of older women in randomized clinical trials: factors associated with taking study medication in the fracture intervention trial. J Am Geriatr Soc. 2000;48(9):1126-31. PubMed
Chan KA, Andrade SE, Boles M, Buist DS, Chase GA, Donahue JG, Goodman MJ, Gurwitz JH, LaCroix AZ, Platt R. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet. 2000;355(9222):2185-8. PubMed
Buist DSM, LaCroix AZ, Barlow WE, White E, Cauley JA, Bauer DC, Weiss NS. Bone mineral density, endogenous hormones, and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev. 2000;9:235.
Buist DSM, LaCroix AZ, Newton KM, Keenan NL. Long-term HRT users. Menopause Digest. 2000;12:210-221.
Buist DSM, LaCroix AZ, Barlow WE, White E, Cauley JA, Bauer DC, Weiss NS. Bone mineral density, endogenous hormones, and risk of postmenopausal breast cancer. Am J Epidemiol. 2000;151:S31.
Anderson LA, Caplan LS, Buist DS, Newton KM, Curry SJ, Scholes D, LaCroix AZ. Perceived barriers and recommendations concerning hormone replacement therapy counseling among primary care providers. Menopause. 1999;6(2):161-6. PubMed
Keenan NL, Anderson LA, LaCroix AZ, Newton KM, Buist DS. Helping women achieve long-term continuance of estrogen replacement therapy(ERT) and hormone replacement therapy. Menopause. 1999;6(2):179-80. PubMed
Buist DS, LaCroix AZ, Newton KM, Keenan NL. Are long-term hormone replacement therapy users different from short-term and never users? Am J Epidemiol. 1999;149(3):275-81. PubMed
Dr. Diana Buist and team reflect on HOME trial showing 50 percent screening boost in underscreened women.
Interdisciplinary group shows that home-based HPV tests can boost cervical cancer screening for women at high risk.
A Kaiser Permanente-led BCSC study is among the largest ever to evaluate adding MRI surveillance for breast cancer survivors.
Kaiser Permanente Share profiles longtime KPWHRI investigator and director of research and strategic partnerships.
Read it in News and Events.
Kaiser Permanente Washington has been part of the national Breast Cancer Surveillance Consortium since 1994. Learn about the Kaiser Permanente Washington Breast Cancer Surveillance Registry here.
HealthDay, Nov 8, 2019